Navigation Links
AMDL Announces Closing of Private Offering

TUSTIN, Calif., Dec. 24 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has conducted the closing of its combined Regulation D/Regulation S private unit offering of 2,007,508 shares of common stock and warrants to purchase 1,003,755 shares of common stock, generating net proceeds of approximately $5,433,000. The shares of AMDL common stock were sold at $3.09 per share and the four year warrants included in the units are exercisable at $4.74 per share. Warrants to purchase an additional 200,751 shares were issued to AMDL's placement agents at the same exercise price. AMDL agreed to file a registration statement within 60 days of the closing to register the resale of the shares of common stock and the shares issuable on exercise of the warrants included in the units and the placement agent warrants. Spencer Clarke, LLC, a FINRA member broker dealer, acted as AMDL's principal placement agent for sales in the United States, and Galileo Asset Management, S.A., a member of the Association Romande des Intermediaries Financier, acted as AMDL's placement agent for sales outside of the United States.

Gary L. Dreher, President of AMDL, said: "The reception to the offering was gratifying under the current economic climate. These funds provide some of the additional working capital we need to expand Jade Pharmaceutical Inc.'s new business opportunities and product development efforts in China and for our other general working capital needs."

About AMDL

AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at

Forward-Looking Statements

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:10/13/2015)... the United States , ... represents about 14% of all new cases of kidney cancer.   ... Canada and Europe .  PRCC represents ... --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces ... AB (publ) ("AstraZeneca") have completed enrolment in a global Phase II ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
(Date:10/12/2015)... 12, 2015 cell surface marker detection ... 2022, according to a new report by Grand View Research, ... in incidence of oncology diseases and other cell-associated disorders. ... to reach USD 6.49 billion by 2022, according to a ... demand can be attributed to rise in incidence of oncology ...
(Date:10/12/2015)... DIEGO , Oct. 12, 2015  Patara ... debilitating allergic and inflammatory diseases and conditions, today ... A preferred stock financing. Concurrent with the close ... entered into a Loan and Security Agreement with ... up to $7 million. Patara will use the ...
Breaking Biology Technology:
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
(Date:9/28/2015)... YORK , Sept. 28, 2015  The ... respiration rate and body temperature, is an essential ... can be indicators of deterioration in a patient,s ... hospital, vital signs are typically taken during routine ... hours. If a patient deteriorates between these observation ...
(Date:9/28/2015)... Synaptics Inc. (NASDAQ: SYNA ), the ... Lenovo has selected Synaptics , Natural ID ™ ... smartphone, the Vibe P1. The new Vibe P1 ... and provide swift access to applications and mobile payments ... FS4202 sensor solution utilizes AES256-bit encryption of the fingerprint ...
Breaking Biology News(10 mins):